Shdaifat Emad, Abu-Sneineh Firas, Alsaleh Nagla, Ibrahim Abdallah
Community Nursing Department, College of Nursing, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia.
Fundamentals Nursing Department, College of Nursing, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province, Saudi Arabia.
Value Health Reg Issues. 2025 Jan;45:101038. doi: 10.1016/j.vhri.2024.101038. Epub 2024 Aug 30.
This study aimed to determine the direct and indirect costs of sickle cell disease (SCD) in Saudi Arabia.
Data were collected from 217 participants aged ≥18 years in the eastern region of Saudi Arabia, using a prevalence-based cost-of-illness approach. The Institute for Medical Technology Assessment Medical Consumption Questionnaire and Institute for Medical Technology Assessment Productivity Cost Questionnaire were used to assess costs. A multistage process was used, encompassing patient data collection over 3 months, cost calculation from clinic visits and drug prices, and extrapolation for annual estimates.
The study revealed substantial societal costs of SCD, with an average per-patient cost of SAR181 899 (US$48 506), covering healthcare and productivity losses. Healthcare costs, including hospitalization, informal care, and medication, averaged SAR80 306 (US$21 415). In addition, productivity costs, including unpaid work and presenteeism, averaged SAR101 594 (US$27 092). Obtaining higher levels of education, such as a diploma and BSc degree or higher, has been found to significantly decrease the costs associated with SCD (P = .016, P = .001). Furthermore, when comparing different employment statuses, students (B = -0.301, P = .058) were found to have marginally lower SCD costs, suggesting that their expenses were lower than those of individuals in other employment categories. The predictive model used in this study explained 11.2% of the variation in costs.
Our study highlights a significant economic burden of SCD in Saudi Arabia and highlights the need for targeted strategies to alleviate financial challenges and improve patient well-being.
本研究旨在确定沙特阿拉伯镰状细胞病（SCD）的直接和间接成本。
采用基于患病率的疾病成本法，从沙特阿拉伯东部地区217名年龄≥18岁的参与者中收集数据。使用医学技术评估医学消费问卷和医学技术评估生产力成本问卷来评估成本。采用多阶段流程，包括3个月内的患者数据收集、门诊就诊和药品价格的成本计算以及年度估计的外推。
该研究揭示了SCD巨大的社会成本，每位患者的平均成本为181899沙特里亚尔（48506美元），涵盖医疗保健和生产力损失。医疗保健成本，包括住院、非正式护理和药物治疗，平均为80306沙特里亚尔（21415美元）。此外，生产力成本，包括无薪工作和出勤主义，平均为101594沙特里亚尔（27092美元）。已发现获得更高水平的教育，如文凭和理学学士学位或更高学位，可显著降低与SCD相关的成本（P = .016，P = .001）。此外，在比较不同就业状况时，发现学生（B = -0.301，P = .058）的SCD成本略低，这表明他们的费用低于其他就业类别的个人。本研究中使用的预测模型解释了成本变化的11.2%。
我们的研究突出了沙特阿拉伯SCD的巨大经济负担，并强调需要有针对性的策略来缓解财务挑战并改善患者福祉。
